Growth factors in the therapy of myelodisplasia: Biological aspects

Maurizio Bonfichi, Cesare Astori, Emilio Paolo Alessandrino, P. B A Balduini, Carlo Castagnola, Ercole Brusamolino, Guido Pagnucco, Angelo Canevari, Paola Trucco, Carlo Bernasconi

Research output: Contribution to journalArticlepeer-review


Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute Leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalLeukemia and Lymphoma
Issue numberSUPPL. 1
Publication statusPublished - 1997


  • Growth factors
  • Myelodisplastic syndromes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Growth factors in the therapy of myelodisplasia: Biological aspects'. Together they form a unique fingerprint.

Cite this